Replimune Group Inc REPL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL
-
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL
-
REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky
-
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL
-
REPL Deadline Alert: SueWallSt Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026
-
REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the Firm
-
REPL Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending October 5, 2026 Lead Plaintiff Deadline for Information About Recovering Their Losses
-
REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt
Trading Information
- Previous Close Price
- $13.24
- Day Range
- $13.06–13.59
- 52-Week Range
- $0.00–16.33
- Bid/Ask
- $13.45 / $13.60
- Shares Outstanding
- 94.22M
- Market Cap
- $1.27B
- Volume/Avg
- 3M / 4M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 465
- Website
- https://www.replimune.com
Valuation
|
Metric
|
REPL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 10.70 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
REPL
|
|---|---|
Quick Ratio | 5.09 |
Current Ratio | 5.23 |
Interest Coverage | −28.91 |
Quick Ratio
REPL
Profitability
|
Metric
|
REPL
|
|---|---|
Return on Assets (Normalized) | −75.41% |
Return on Equity (Normalized) | −123.82% |
Return on Invested Capital (Normalized) | −84.07% |
Return on Assets
REPL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|CzQ&?< | LOCK|@$BH | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@rWpG&> | LOCK|Ck!q | $76B | |||
| Moderna Inc
MRNA
| LOCK|cTj<Tv | LOCK|GV@ | $75B | |||
| argenx SE ADR
ARGX
| LOCK|Kn%nS? | LOCK|xm | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&fNrGWf | LOCK|QT< | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<<Y#&^ | LOCK|Q%j@# | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^%V>cN# | LOCK|&&ySx | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|>ls?pvN | LOCK|C@t | $24B | |||
| Incyte Corp
INCY
| LOCK|<v#mvkN | LOCK|!M@ | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<?H>?g | LOCK|n<n | $15B |
United States